<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39318534</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers.</ArticleTitle><Pagination><StartPage>110839</StartPage><MedlinePgn>110839</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110839</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.110839</ELocationID><Abstract><AbstractText>Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (<i>n</i> = 85 each). Biomarkers were assessed 12-24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16<sup>bright</sup>CD56<sup>-</sup> cell presence distinguished PCC individuals from recovered patients with &gt;88% accuracy and &lt;92% precision.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliván-Blázquez</LastName><ForeName>Bárbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bona-Otal</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Navarre Health Service, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Méndez-López</LastName><ForeName>Fátima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerma-Irureta</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Izuel</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibáñez-Ruiz</LastName><ForeName>Jesús</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montolío</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Herreros</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tarazona Primary Health Care Center, Aragonese Healthcare Service (SALUD), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godino</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cell Separation and Flow Cytometry Core, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimeno-Beltran</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cell Separation and Flow Cytometry Core, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Encabo-Berzosa</LastName><ForeName>María Del Mar</ForeName><Initials>MDM</Initials><AffiliationInfo><Affiliation>Biobank of the Aragon Health System, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenaz</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biobank of the Aragon Health System, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medel-Martínez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Placental Pathophysiology &amp; Fetal Programming Research Group, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casado-Vicente</LastName><ForeName>Verónica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Parquesol University Health Center, Castilla y León Health Service (SACYL), University Teaching Unit of Family and Community Medicine, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coiras</LastName><ForeName>Mayte</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tellería-Orriols</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoorlemmer</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Endogenous Retroviruses (ERVs) in Development and Disease Group, Instituto Aragonés deCiencias de la Salud (IACS), Zaragoza, Spain; and ARAID Foundation, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magallón-Botaya</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biochemistry</Keyword><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39318534</ArticleId><ArticleId IdType="pmc">PMC11420445</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.110839</ArticleId><ArticleId IdType="pii">S2589-0042(24)02064-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cascella M., Rajnik M., Aleem A., Dulebohn S.C., Di Napoli R. StatPearls Publishing; 2023. Features, Evaluation, and Treatment of Coronavirus (COVID-19)</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO Coronavirus (COVID-19) Dashboard. 2023. https://covid19.who.int/</Citation></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626–631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E., Tebé C., Fernandez-Bertolin S., Aragon M., Recalde M., Roel E., Prats-Uribe A., Prieto-Alhambra D., Duarte-Salles T. The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat. Commun. 2021;12:777. doi: 10.1038/s41467-021-21100-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21100-y</ArticleId><ArticleId IdType="pmc">PMC7858639</ArticleId><ArticleId IdType="pubmed">33536436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: What do we know about “long covid”. BMJ. 2020;m2815:m2815. doi: 10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics (UK)  The prevalence of long COVID symptoms and COVID-19 complications. 2020. https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications</Citation></Reference><Reference><Citation>WHO  Post COVID-19 condition (Long COVID) 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Greenhalgh T., Knight M., A’Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133–146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfì A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603–605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Service in England (NHS)  Long-term effects of coronavirus (long COVID) 2021. https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/</Citation></Reference><Reference><Citation>Rojas-Bolivar D., Huaroto-Ramírez F., Curisinche-Rojas M., Gonzales Zurita D., Gutiérrez E. Prevalence, clinical manifestations, and associated factors of long COVID-19. Revista de la Facultad de Medicina Humana. 2022;22:572–583. doi: 10.25176/RFMH.v22i3.5009.</Citation><ArticleIdList><ArticleId IdType="doi">10.25176/RFMH.v22i3.5009</ArticleId></ArticleIdList></Reference><Reference><Citation>Odak I., Barros-Martins J., Bošnjak B., Stahl K., David S., Wiesner O., Busch M., Hoeper M.M., Pink I., Welte T., et al. Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine. 2020;57:102885. doi: 10.1016/j.ebiom.2020.102885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102885</ArticleId><ArticleId IdType="pmc">PMC7338277</ArticleId><ArticleId IdType="pubmed">32650275</ArticleId></ArticleIdList></Reference><Reference><Citation>Uranga-Murillo I., Morte E., Hidalgo S., Pesini C., García-Mulero S., Sierra J.L., Santiago L., Arias M., De Miguel D., Encabo-Berzosa M.D.M., et al. Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes. Theranostics. 2022;12:290–306. doi: 10.7150/thno.63463.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.63463</ArticleId><ArticleId IdType="pmc">PMC8690910</ArticleId><ArticleId IdType="pubmed">34987646</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni P., Neri M., D’Errico S., Alfieri L., Bonuccelli D., Cingolani M., Di Paolo M., Gaudio R.M., Lestani M., Marti M., et al. Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1β, IL-6, IL-15 and TNF-α. Forensic Sci. Med. Pathol. 2022;18:4–19. doi: 10.1007/s12024-021-00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12024-021-00414-9</ArticleId><ArticleId IdType="pmc">PMC8406387</ArticleId><ArticleId IdType="pubmed">34463916</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller S., Schultze J.L. Systems analysis of human innate immunity in COVID-19. Semin. Immunol. 2023;68:101778. doi: 10.1016/j.smim.2023.101778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2023.101778</ArticleId><ArticleId IdType="pmc">PMC10201327</ArticleId><ArticleId IdType="pubmed">37267758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Nigoghossian C.D., Ageno W., Madjid M., Guo Y., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J. Am. Coll. Cardiol. 2020;75:2950–2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Forconi C.S., Oduor C.I., Oluoch P.O., Ong’echa J.M., Münz C., Bailey J.A., Moormann A.M. A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases. Front. Cell. Infect. Microbiol. 2020;10:162. doi: 10.3389/fcimb.2020.00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00162</ArticleId><ArticleId IdType="pmc">PMC7186373</ArticleId><ArticleId IdType="pubmed">32373555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu P.F., Hultin L.E., Hultin P., Hausner M.A., Hirji K., Jewett A., Bonavida B., Detels R., Giorgi J.V. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995;10:331–340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7552495</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210–216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H.E., Goldberg S.A., Forman C.A., Munter S.E., Hoh R., Tai V., et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2021;224:1839–1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolato B., Carvalho A.F., Soczynska J.K., Perini G.I., McIntyre R.S. The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr. Neuropharmacol. 2015;13:558–576. doi: 10.2174/1570159X13666150630171433.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X13666150630171433</ArticleId><ArticleId IdType="pmc">PMC4761629</ArticleId><ArticleId IdType="pubmed">26467407</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Guevara-Coto J., Yogendra R., Francisco E.B., Long E., Pise A., Rodrigues H., Parikh P., Mora J., Mora-Rodríguez R.A. Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. Front. Immunol. 2021;12:700782. doi: 10.3389/fimmu.2021.700782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Katze M.G., He Y., Gale M. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2002;2:675–687. doi: 10.1038/nri888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri888</ArticleId><ArticleId IdType="pubmed">12209136</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Rubaye H.T., Almulla A.F., Al-Hadrawi D.S., Maes M. Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection. J. Clin. Med. 2023;12:511. doi: 10.3390/jcm12020511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12020511</ArticleId><ArticleId IdType="pmc">PMC9865328</ArticleId><ArticleId IdType="pubmed">36675440</ArticleId></ArticleIdList></Reference><Reference><Citation>Acanfora D., Nolano M., Acanfora C., Colella C., Provitera V., Caporaso G., Rodolico G.R., Bortone A.S., Galasso G., Casucci G. Impaired Vagal Activity in Long-COVID-19 Patients. Viruses. 2022;14:1035. doi: 10.3390/v14051035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051035</ArticleId><ArticleId IdType="pmc">PMC9147759</ArticleId><ArticleId IdType="pubmed">35632776</ArticleId></ArticleIdList></Reference><Reference><Citation>Low R.N., Low R.J., Akrami A. A review of cytokine-based pathophysiology of Long COVID symptoms. Front. Med. 2023;10:1011936. doi: 10.3389/fmed.2023.1011936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1011936</ArticleId><ArticleId IdType="pmc">PMC10103649</ArticleId><ArticleId IdType="pubmed">37064029</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro D., Sharma S. StatPearls Publishing; 2023. Hypokalemia.</Citation><ArticleIdList><ArticleId IdType="pubmed">29494072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondon H., Badireddy M. StatPearls Publishing; 2023. Hyponatremia.</Citation><ArticleIdList><ArticleId IdType="pubmed">29262111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortelli P., Ferrazzoli D., Sebastianelli L., Maestri R., Dezi S., Spampinato D., Saltuari L., Alibardi A., Engl M., Kofler M., et al. Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID-19. Eur. J. Neurol. 2022;29:1652–1662. doi: 10.1111/ene.15278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15278</ArticleId><ArticleId IdType="pmc">PMC9111319</ArticleId><ArticleId IdType="pubmed">35138693</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Khan M.A., Putrino D., Woodcock A., Kell D.B., Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 2023;34:321–344. doi: 10.1016/j.tem.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín A.I., Priego T., Moreno-Ruperez Á., González-Hedström D., Granado M., López-Calderón A. IGF-1 and IGFBP-3 in Inflammatory Cachexia. Int. J. Mol. Sci. 2021;22:9469. doi: 10.3390/ijms22179469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179469</ArticleId><ArticleId IdType="pmc">PMC8430490</ArticleId><ArticleId IdType="pubmed">34502376</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanevich O.V., Alekseeva E.I., Sergeeva M., Fadeev A.V., Komissarova K.S., Ivanova A.A., Simakova T.S., Vasilyev K.A., Shurygina A.-P., Stukova M.A., et al. SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19. Nat. Commun. 2023;14:149. doi: 10.1038/s41467-022-34033-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34033-x</ArticleId><ArticleId IdType="pmc">PMC9831376</ArticleId><ArticleId IdType="pubmed">36627290</ArticleId></ArticleIdList></Reference><Reference><Citation>Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 2008;180:5771–5777. doi: 10.4049/jimmunol.180.9.5771.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.9.5771</ArticleId><ArticleId IdType="pubmed">18424693</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Vito C., Calcaterra F., Coianiz N., Terzoli S., Voza A., Mikulak J., Della Bella S., Mavilio D. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications. Front. Immunol. 2022;13:888248. doi: 10.3389/fimmu.2022.888248.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.888248</ArticleId><ArticleId IdType="pmc">PMC9279859</ArticleId><ArticleId IdType="pubmed">35844604</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine R.L. Addressing the Long-term Effects of COVID-19. JAMA. 2022;328:823–824. doi: 10.1001/jama.2022.14089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.14089</ArticleId><ArticleId IdType="pubmed">35921084</ArticleId></ArticleIdList></Reference><Reference><Citation>Iosef C., Knauer M.J., Nicholson M., Van Nynatten L.R., Cepinskas G., Draghici S., Han V.K.M., Fraser D.D. Plasma proteome of Long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function. J. Transl. Med. 2023;21:377. doi: 10.1186/s12967-023-04149-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04149-9</ArticleId><ArticleId IdType="pmc">PMC10257382</ArticleId><ArticleId IdType="pubmed">37301958</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.A., Knauer M.J., Nicholson M., Daley M., Van Nynatten L.R., Martin C., Patterson E.K., Cepinskas G., Seney S.L., Dobretzberger V., et al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol. Med. 2022;28:122. doi: 10.1186/s10020-022-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00548-8</ArticleId><ArticleId IdType="pmc">PMC9549814</ArticleId><ArticleId IdType="pubmed">36217108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamga E., Soulé A., Piché A., Emad A., Durand M., Rousseau S. Validation of ANG-1 and P-SEL as biomarkers of post-COVID-19 conditions using data from the Biobanque québécoise de la COVID-19 (BQC-19) Clin. Proteomics. 2023;20:44. doi: 10.1186/s12014-023-09436-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-023-09436-7</ArticleId><ArticleId IdType="pmc">PMC10594676</ArticleId><ArticleId IdType="pubmed">37875801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T., Hanson S.W., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., Blyuss O., Bobkova P., Bonsel G., et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–1615. doi: 10.1001/JAMA.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheskin D.J. Chapman and Hall/CRC; 2020. Handbook of Parametric and Nonparametric Statistical Procedures Fifth.</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9780429186196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>